NCT07373574

Brief Summary

This is a research study conducted by Standard Process, Inc. and the University of North Carolina and Chapel Hill Nutrition Research Institute, which aims to evaluate the effectiveness of nutritional supplementation in improving the health of fingernails and hair.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
10mo left

Started Jun 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress17%
Jun 2026May 2027

First Submitted

Initial submission to the registry

September 24, 2025

Completed
4 months until next milestone

First Posted

Study publicly available on registry

January 28, 2026

Completed
4 months until next milestone

Study Start

First participant enrolled

June 1, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2027

Last Updated

June 1, 2026

Status Verified

April 1, 2026

Enrollment Period

11 months

First QC Date

September 24, 2025

Last Update Submit

May 28, 2026

Conditions

Keywords

NutritionHair HealthNail Health

Outcome Measures

Primary Outcomes (2)

  • Determine the effects of test products (TP1/2) versus active control (AC) on numbers and severity of longitudinal (vertical) nail ridges

    Changes in scores of vertical nail ridge numbers and severity according to Nail Score Chart will be determined at baseline (scores and pictures at V2), at 3 months (pictures only at V3) and 6 months (scores and pictures at V4) of supplementation

    6 months

  • Determine the effects of TP1/2 versus AC on nail biostructure and biochemical composition after 6 months of supplementation

    Changes in Raman spectra of fingernail tissue at baseline (V2) compared to month 6 (V4) of supplementation

    6 months

Secondary Outcomes (3)

  • Determine the effects of test products TP1/2 versus AC on density, thickness and pigmentation of hair

    6 months

  • Determine the effects of TP1/2 versus AC on near vision (visual accommodation)

    6 months

  • Determine the effects of TP1/2 versus AC on the scores of general health questionnaire

    6 months

Other Outcomes (96)

  • Assess the safety and tolerability of TP1/2 and AC in healthy participants

    6 months

  • Anthropometrics

    6 months

  • Vitals

    6 months

  • +93 more other outcomes

Study Arms (3)

Congaplex

EXPERIMENTAL

TP1: 6 capsules/day

Dietary Supplement: Immune Health (Congaplex)

Immuplex

EXPERIMENTAL

TP2: 6 capsules/day

Dietary Supplement: Immune Health (Immuplex)

Gastro-Fiber

ACTIVE COMPARATOR

AC: 6 capsules/day

Dietary Supplement: Active Control (Gastro-Fiber)

Interventions

Immune Health (Congaplex)DIETARY_SUPPLEMENT

Supplement related to nail, hair, and immune health

Congaplex

Supplement not related to immune, hair, or nail health

Gastro-Fiber
Immune Health (Immuplex)DIETARY_SUPPLEMENT

Supplement related to nail, hair, and immune health

Immuplex

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy female and male adults who are 18 to 75 years of age (inclusive)
  • Display longitudinal (vertical) nail ridges in the absence of other nail abnormalities
  • No cosmetic nail treatments that would mask the natural appearance of the nail plate in the past 6 months (i.e., manicure procedures that smooth the nail surface, nail polish)
  • In good general health (no uncontrolled diseases or conditions) as deemed by the investigator and is able to consume the study product
  • Individuals with childbearing potential must agree to practice an acceptable form of birth control for a certain timeframe prior to the first dose of study product and throughout the study, including:
  • use for at least 3 months prior to the first dose of study product: hormonal contraceptives including oral contraceptives, hormone birth control patch (e.g., Ortho Evra), vaginal contra-ceptive ring (e.g., NuvaRing), injectable contraceptives (e.g., Depo-Provera, Lunelle), or hormone implant (e.g., Norplant System), or intrauterine devices (e.g., Mirena); or
  • use for at least 1 month prior to the first dose of study product: double-barrier method, non-hormonal intrauterine devices (i.e., copper), or complete abstinence from sexual inter-course that may result in pregnancy; or
  • vasectomy of partner at least 6 months prior to the first dose of study product Individuals with the potential to impregnate others must agree to use condoms or other acceptable methods to prevent pregnancy throughout the study. Complete abstinence from sexual intercourse that may result in pregnancy is also acceptable.
  • Agree to refrain from treatments listed in Section 8.3 in the defined timeframe
  • Have maintained stable dietary habits (including supplement intake), exercise habits and lifestyle for the last 3 months prior to screening and agree to maintain dietary and exercise habits and lifestyle throughout the study
  • Willing and able to agree to the requirements and restrictions of this study, be willing to give volun-tary consent, be able to understand and read the questionnaire, and carry out all study-related pro-cedures

You may not qualify if:

  • Individuals who are lactating, pregnant or planning to become pregnant during the study as con-firmed at the baseline visit (Visit 2)
  • Individuals who have applied cosmetic/topical treatments to fingernails in the past 6 months (i.e., manicures with nail plate filing, nail polish)
  • Individuals who display nail abnormalities indicative of a health condition affecting nail appearance or have been diagnosed with a disease affecting nails (i.e., thickening, discoloration, horizontal nail ridges \[Beau's lines\])
  • Individuals with active nail biting (onychophagia) or other behaviors that may affect nail integrity
  • Have a known sensitivity, intolerability, or allergy to any of the study products or their excipients
  • Currently has COVID-19 or tests positive for COVID-19 within 28 days prior to baseline visit
  • Individuals opposed to consuming animal products
  • Have a history of uncontrolled hypertension (140/90 or greater mmHg), kidney dysfunction or dis-ease (dialysis or renal failure), hepatic impairment or disease
  • Individuals who lack the capacity to provide informed consent, as determined by the study team based on cognitive impairment, altered mental status, or inability to understand the study and make an informed decision

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (28)

  • Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001 Jul;33(5):350-7. doi: 10.3109/07853890109002089.

    PMID: 11491194BACKGROUND
  • Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982 Jul;94(1):91-6.

    PMID: 7091289BACKGROUND
  • Kim DY, Ahn H, Lee S, Jun I, Seo KY, Kim SY, Kim TI. Efficacy of a new refractive multifocal contact lens for presbyopia. Sci Rep. 2024 Apr 17;14(1):8878. doi: 10.1038/s41598-024-55918-5.

    PMID: 38632261BACKGROUND
  • Ozeren E. Is C-reactive protein-albumin ratio or neutrophil-lymphocyte ratio a better indicator to predict in-hospital mortality in traumatic brain injury? Ulus Travma Acil Cerrahi Derg. 2022 Oct;28(10):1482-1487. doi: 10.14744/tjtes.2022.00794.

    PMID: 36169474BACKGROUND
  • Baccaglini L, Theriaque DW, Shuster JJ, Serrano G, Lalla RV. Validation of anamnestic diagnostic criteria for recurrent aphthous stomatitis. J Oral Pathol Med. 2013 Apr;42(4):290-4. doi: 10.1111/jop.12015. Epub 2012 Oct 27.

    PMID: 23106421BACKGROUND
  • Karincaoglu Y, Batcioglu K, Erdem T, Esrefoglu M, Genc M. The levels of plasma and salivary antioxidants in the patient with recurrent aphthous stomatitis. J Oral Pathol Med. 2005 Jan;34(1):7-12. doi: 10.1111/j.1600-0714.2004.00253.x.

    PMID: 15610400BACKGROUND
  • Arikan S, Durusoy C, Akalin N, Haberal A, Seckin D. Oxidant/antioxidant status in recurrent aphthous stomatitis. Oral Dis. 2009 Oct;15(7):512-5. doi: 10.1111/j.1601-0825.2009.01580.x.

    PMID: 19761497BACKGROUND
  • Edgar NR, Saleh D, Miller RA. Recurrent Aphthous Stomatitis: A Review. J Clin Aesthet Dermatol. 2017 Mar;10(3):26-36. Epub 2017 Mar 1.

    PMID: 28360966BACKGROUND
  • Tappuni AR, Kovacevic T, Shirlaw PJ, Challacombe SJ. Clinical assessment of disease severity in recurrent aphthous stomatitis. J Oral Pathol Med. 2013 Sep;42(8):635-41. doi: 10.1111/jop.12059. Epub 2013 Mar 19.

    PMID: 23509958BACKGROUND
  • Sanchez-Bernal J, Conejero C, Conejero R. Recurrent Aphthous Stomatitis. Actas Dermosifiliogr (Engl Ed). 2020 Jul-Aug;111(6):471-480. doi: 10.1016/j.ad.2019.09.004. Epub 2020 May 22. English, Spanish.

    PMID: 32451064BACKGROUND
  • Chang H, Johnson E, Khoo C, Wang W, Gu L. Cranberry Juice Polyphenols Inhibited the Formation of Advanced Glycation End Products in Collagens, Inhibited Advanced Glycation End Product-Induced Collagen Crosslinking, and Cleaved the Formed Crosslinks. J Agric Food Chem. 2022 Dec 14;70(49):15560-15569. doi: 10.1021/acs.jafc.2c06502. Epub 2022 Dec 1.

    PMID: 36455288BACKGROUND
  • Haus JM, Carrithers JA, Trappe SW, Trappe TA. Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol (1985). 2007 Dec;103(6):2068-76. doi: 10.1152/japplphysiol.00670.2007. Epub 2007 Sep 27.

    PMID: 17901242BACKGROUND
  • Aggarwala KRG. Ocular Accommodation, Intraocular Pressure, Development of Myopia and Glaucoma: Role of Ciliary Muscle, Choroid and Metabolism. Med Hypothesis Discov Innov Ophthalmol. 2020;9(1):66-70. Epub 2020 Jan 5.

    PMID: 31976346BACKGROUND
  • Kuzuhara A, Fujiwara N, Hori T. Analysis of internal structure changes in black human hair keratin fibers with aging using Raman spectroscopy. Biopolymers. 2007 Oct 5-15;87(2-3):134-40. doi: 10.1002/bip.20805.

    PMID: 17626296BACKGROUND
  • Brito ALB, Bruggen C, Ildiz GO, Fausto R. Investigation of menopause-induced changes on hair by Raman spectroscopy and chemometrics. Spectrochim Acta A Mol Biomol Spectrosc. 2022 Jul 5;275:121175. doi: 10.1016/j.saa.2022.121175. Epub 2022 Mar 21.

    PMID: 35344858BACKGROUND
  • Jain N, Doshi B, Khopkar U. Trichoscopy in alopecias: diagnosis simplified. Int J Trichology. 2013 Oct;5(4):170-8. doi: 10.4103/0974-7753.130385.

    PMID: 24778525BACKGROUND
  • Park AM, Khan S, Rawnsley J. Hair Biology: Growth and Pigmentation. Facial Plast Surg Clin North Am. 2018 Nov;26(4):415-424. doi: 10.1016/j.fsc.2018.06.003. Epub 2018 Aug 16.

    PMID: 30213423BACKGROUND
  • Gniadecka M, Faurskov Nielsen O, Christensen DH, Wulf HC. Structure of water, proteins, and lipids in intact human skin, hair, and nail. J Invest Dermatol. 1998 Apr;110(4):393-8. doi: 10.1046/j.1523-1747.1998.00146.x.

    PMID: 9540981BACKGROUND
  • Fawcett RS, Linford S, Stulberg DL. Nail abnormalities: clues to systemic disease. Am Fam Physician. 2004 Mar 15;69(6):1417-24.

    PMID: 15053406BACKGROUND
  • Yin J, Ibrahim S, Petersen F, Yu X. Autoimmunomic Signatures of Aging and Age-Related Neurodegenerative Diseases Are Associated With Brain Function and Ribosomal Proteins. Front Aging Neurosci. 2021 May 28;13:679688. doi: 10.3389/fnagi.2021.679688. eCollection 2021.

    PMID: 34122052BACKGROUND
  • Hanlon PR, Robbins MG, Scholl C, Barnes DM. Aqueous extracts from dietary supplements influence the production of inflammatory cytokines in immortalized and primary T lymphocytes. BMC Complement Altern Med. 2009 Dec 14;9:51. doi: 10.1186/1472-6882-9-51.

    PMID: 20003431BACKGROUND
  • Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2019 Apr 23;321(16):1610-1620. doi: 10.1001/jama.2019.3087.

    PMID: 31012939BACKGROUND
  • Blumberg J. Nutritional needs of seniors. J Am Coll Nutr. 1997 Dec;16(6):517-23.

    PMID: 9430078BACKGROUND
  • Ramaa CS, Shirode AR, Mundada AS, Kadam VJ. Nutraceuticals--an emerging era in the treatment and prevention of cardiovascular diseases. Curr Pharm Biotechnol. 2006 Feb;7(1):15-23. doi: 10.2174/138920106775789647.

    PMID: 16472130BACKGROUND
  • Sachdeva V, Roy A, Bharadvaja N. Current Prospects of Nutraceuticals: A Review. Curr Pharm Biotechnol. 2020;21(10):884-896. doi: 10.2174/1389201021666200130113441.

    PMID: 32000642BACKGROUND
  • Bruins MJ, Van Dael P, Eggersdorfer M. The Role of Nutrients in Reducing the Risk for Noncommunicable Diseases during Aging. Nutrients. 2019 Jan 4;11(1):85. doi: 10.3390/nu11010085.

    PMID: 30621135BACKGROUND
  • Odden MC, Coxson PG, Moran A, Lightwood JM, Goldman L, Bibbins-Domingo K. The impact of the aging population on coronary heart disease in the United States. Am J Med. 2011 Sep;124(9):827-33.e5. doi: 10.1016/j.amjmed.2011.04.010. Epub 2011 Jun 30.

    PMID: 21722862BACKGROUND
  • Musillo C, Borgi M, Saul N, Moller S, Luyten W, Berry A, Cirulli F. Natural products improve healthspan in aged mice and rats: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2021 Feb;121:89-105. doi: 10.1016/j.neubiorev.2020.12.001. Epub 2020 Dec 9.

    PMID: 33309907BACKGROUND

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 24, 2025

First Posted

January 28, 2026

Study Start

June 1, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 31, 2027

Last Updated

June 1, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share